Skip to main content

José Antonio Arranz Amo

Institutions of which they are part

Postdoctoral researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca

José Antonio Arranz Amo

Institutions of which they are part

Postdoctoral researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca

Projects

Desarrollo de una nueva terapia de reemplazo enzimático basada en nanotecnología para la enfermedad de Parkinson: restablecimiento de la actividad glucocerebrosidasa lisosomal mediante nanoconjugación enzima-polímero de GBA (NANO-ERT).

IP: Marta Martínez Vicente
Collaborators: Eddie Pradas Gracia, David Moreno Martinez, José Antonio Arranz Amo, Maria Camprodon Gomez, Laura Castillo Ribelles, Clara Carnicer Cáceres
Funding agency: Fundación Banco Bilbao Vizcaya Argentaria
Funding: 124047.74
Reference: BBVA/INVESTIGACIO/MARTINEZ
Duration: 01/05/2020 - 30/07/2023

Enfermedades minoritarias causantes de degeneración de ganglios basales en pedriatría: implemementación combinada del análisis genómico y de biomarcadores.

IP: Belen Perez Dueñas
Collaborators: José Antonio Arranz Amo, Josefa Élida Vázquez Méndez, Alfons Macaya Ruíz, Anna Marcé Grau, Clara Carnicer Cáceres, Mireia Del Toro Riera, Ana Felipe Rucián
Funding agency: Instituto de Salud Carlos III
Funding: 196020
Reference: PI18/01319
Duration: 01/01/2019 - 31/12/2022

Apolipoproteína AIb como biomarcador y diana terapéutica de la glomeruloesclerosis segmentaria y focal idiopática (GESF)

IP: Joan López Hellin
Collaborators: José Antonio Arranz Amo, Joana Sellarés Roig, Maria Teresa Salcedo Allende, Concepció Jacobs Cachá
Funding agency: Instituto de Salud Carlos III
Funding: 88935
Reference: PI14/00275
Duration: 01/01/2015 - 30/06/2018

Neurodegeneración en la cirrosis hepática: relación con el metabolismo nitrogenado y la inflamación

IP: -
Collaborators: José Antonio Arranz Amo, Xavier Nuvials Casals, Macarena Simon-Talero Horga
Funding agency: Instituto de Salud Carlos III
Funding: 215544.56
Reference: PI11/00954
Duration: 01/01/2012 - 31/03/2016

Related news

The project aims to improve prevention, diagnosis, and treatment through computational biomedicine, innovative therapies, and the transfer of knowledge into clinical practice.

The annual event offered a space for dialogue between the scientific community and society on how to address the future of ageing through research and innovation.

Docetaxel, carried by Soluplus, proved to be the most effective and least toxic combination to cross the blood-brain barrier and attack the tumour directly.

Related professionals

Sara Garcia Ortega

Sara Garcia Ortega

Predoctoral researcher
Translational Molecular Pathology
Read more
Paula Isabel Roldan Caballero

Paula Isabel Roldan Caballero

Research Support. Licensed Technician
Clinical Research Development Directorate
Read more
Martina Garriga Ferrer

Martina Garriga Ferrer

Gestor/a. Nivell 3.2
Internal Strategy Directorate
Read more
Beatriz  Soria Navarro

Beatriz Soria Navarro

Predoctoral researcher
Shock, Organ Dysfunction and Resuscitation
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.